Baxter International (NYSE:BAX) Given New $19.00 Price Target at The Goldman Sachs Group

Baxter International (NYSE:BAX) had its price objective raised by The Goldman Sachs Group from $17.00 to $19.00 in a research note issued to investors on Friday,MarketScreener reports.

BAX has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baxter International in a report on Wednesday, January 21st. Barclays upped their target price on shares of Baxter International from $25.00 to $27.00 in a research report on Friday. Jefferies Financial Group dropped their target price on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Citigroup dropped their target price on shares of Baxter International from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Finally, Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $19.91.

Baxter International Trading Down 1.8%

NYSE:BAX traded down $0.33 during trading hours on Friday, hitting $17.26. 10,872,013 shares of the stock were exchanged, compared to its average volume of 7,258,698. The company’s 50 day moving average is $17.92 and its two-hundred day moving average is $19.18. Baxter International has a twelve month low of $15.73 and a twelve month high of $32.68. The company has a quick ratio of 1.56, a current ratio of 2.31 and a debt-to-equity ratio of 1.55. The company has a market capitalization of $8.91 billion, a P/E ratio of -9.33, a price-to-earnings-growth ratio of 1.24 and a beta of 0.62.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.05. Baxter International had a positive return on equity of 15.65% and a negative net margin of 9.70%.The firm had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.62 billion. During the same quarter in the prior year, the business earned $0.62 EPS. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Baxter International will post 1.91 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Friday, May 29th will be given a $0.01 dividend. The ex-dividend date is Friday, May 29th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio is currently -2.16%.

Hedge Funds Weigh In On Baxter International

Institutional investors and hedge funds have recently modified their holdings of the business. Imprint Wealth LLC acquired a new position in shares of Baxter International in the 3rd quarter valued at approximately $27,000. Basepoint Wealth LLC bought a new stake in Baxter International during the 4th quarter worth approximately $26,000. MUFG Securities EMEA plc bought a new stake in Baxter International during the 2nd quarter worth approximately $46,000. Los Angeles Capital Management LLC bought a new stake in Baxter International during the 4th quarter worth approximately $46,000. Finally, McMillan Office Inc. bought a new stake in Baxter International during the 4th quarter worth approximately $54,000. 90.19% of the stock is currently owned by institutional investors and hedge funds.

More Baxter International News

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Q1 beat on revenue and EPS — Baxter reported $0.36 EPS vs. consensus $0.31 and $2.70B in revenue (vs. $2.62B expected); top-line growth was driven by strong demand in its medical products & therapies unit. Baxter beats quarterly expectations on strong demand for medical devices
• Positive Sentiment: Overseas sales and segment strength supported the beat and were singled out on the call/presentation, which helped push shares higher initially. Baxter International Inc. 2026 Q1 – Results – Earnings Call Presentation
• Neutral Sentiment: Management reiterated its 2026 growth views and emphasized execution improvements—this supports forward confidence but may not be enough to offset near-term margin concerns. Baxter Posts 1Q Loss, Backs 2026 Growth Views
• Neutral Sentiment: Dividend update: Baxter declared a token quarterly dividend of $0.01 per share (annualized yield ~0.2%); modest cash return that is unlikely to drive significant share moves. (No link)
• Neutral Sentiment: Detailed earnings call transcript and slide deck are available for investors who want granular guidance and margin commentary. Baxter International Inc. (BAX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Margins contracted and net income metrics remain weak — EPS declined year-over-year (from $0.62 to $0.36) and commentary noted margin pressure, which caps enthusiasm despite the beat. BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
• Negative Sentiment: Evercore cut its price target for BAX (while keeping an Outperform rating), signaling analyst caution and likely weighing on the stock. Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.